Changes in lymphoid tissue proliferation with PD-1 inhibitor therapy for lung cancer using FLT-PET/MRI; a retrospective study
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000052404
- Lead Sponsor
- niversity of Fukui
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with metallic device in their body. 2) Patients with claustrophobia. 3) Pregnant or lactating woman. 4) Other cases attending physician it is determined unsuitable for registration of the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage change in FLT accumulation in lymphoid tissues (spleen and bone marrow) before and after PD-1 inhibitor treatment and tumor response to PD-1 inhibitor treatment
- Secondary Outcome Measures
Name Time Method Relationship between FLT accumulation and patient background (gender, age, height, weight, BMI, smoking history, comorbidities, previous treatment), blood test data and its rate of change (white blood cell count, neutrophil count, lymphocyte count, red blood cell count, hemoglobin, platelet count, RDW, CRP, T.bil, AST, ALT, LDH, BUN, Cr, albumin, tumor markers). Percentage change in FLT accumulation in lymphoid tissue before and after PD-1 inhibitor treatment and its association with progression-free survival and overall survival for PD-1 antibody treatment.